Llusern Scientific
Rapid molecular UTI diagnostics for near-patient testing and antibiotic stewardship
| Deal Type | Equity |
|---|---|
| Sector | HealthTech & Digital Health |
| Geography | United Kingdom |
| Stage / Vintage | Commercialisation / seed |
| Total Fundraise | GBP 1M target |
| Minimum Ticket | N/D |
Opportunity Overview
Llusern Scientific is commercialising Lodestar DX, a portable molecular diagnostic system for urinary tract infections. Lodestar detects uropathogen DNA directly from urine using LAMP technology and returns results in around 35 minutes, compared with three or more days for standard culture pathways. The company positions the system as a way to rule out infection, identify bacteria in mixed-growth samples, support tailored antibiotic treatment and reduce unnecessary prescriptions. The platform is UKCA marked, CE-IVD is targeted for Q2 2026, and Llusern has ISO 13485 manufacturing capability. Early commercial traction includes private urology clinics, an MOU with Fujifilm Healthcare UK for mobile diagnostic settings, an SBRI contract and evaluations in care-home pathways.
Key Highlights
- 35-minute near-patient UTI result versus three or more days for culture-based pathways.
- Detects pathogens responsible for the large majority of UTI cases and reports accuracy in the 86% to 91% range versus laboratory culture.
- Recurring revenue model through single-use test panels and potential reagent-rental deployment.
- Early traction across urology clinics, pregnancy pathways, mobile diagnostics and falls / frailty care settings.
- Patient testimonials emphasise speed, proof of infection where standard tests failed, and improved confidence in treatment decisions.
GCC Relevance
Lodestar is relevant to GCC priorities around antimicrobial resistance, decentralised diagnostics, women's health, elderly care and hospital efficiency. The portability of the device could support private clinics, community care and mobile diagnostic channels, but no GCC distribution agreement is disclosed in the materials.